Rinvoq hits goals of Phase III study in psoriatic arthritis

AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase III SELECT-PsA 1 clinical trial of its Rinvoq (upadacitinib), which was approved by the US Food and Drug Administration last August and in Europe in December, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

In this study, both doses of Rinvoq - 15mg and 30mg, once daily - met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).

Rinvoq also demonstrated significant improvements in signs and symptoms of the disease across a variety of endpoints compared to placebo. Rinvoq, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily therapy in psoriatic arthritis and multiple immune-mediated inflammatory diseases.